Pluristem Therapeutics, a developer of placenta-based cell therapies, has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of ...
Tags: 3D Cell Expansion, Pluristem
The Israeli Ministry of Health (IMH) has approved Pluristem Therapeutics’ request to start a Phase II trial using its PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC). IC is a subset of peripheral ...
Tags: clinical study, Medicine
Cha Bio&Diostech, a South Korean partner of Pluristem Therapeutics, has filed its first investigational new drug (IND) application for Pluristem’s PLacental eXpanded (PLX) cells with the Korean Food and Drug Administration (KFDA). ...
Tags: PLX Cells, Cha Bio&Diostech
The USFDA has granted orphan drug designation to Pluristem Therapeutics' PLacental eXpanded (PLX) cells to treat aplastic anemia. The failure of hematopoietic stem cells (HSCs) present in the bone marrow to produce red blood cells, white ...
Tags: orphan drug, aplastic anemia, drug
Pluristem Therapeutics has gained Paul-Ehrlich-Institute (PEI) approval to begin Phase I/II study for muscle regeneration in Germany. The randomized, double blind, placebo controlled study will assess the safety and efficacy of its PLX ...
Tags: Paul-Ehrlich-Institute, PEI, PLX cells
Pluristem Therapeutics, a developer of placenta-based cell therapies, is seeking FDA orphan drug status for its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia. Pluristem earlier received an orphan drug status from the ...